These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32910809)

  • 1. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients.
    Al-Shaer MH; Rubido E; Cherabuddi K; Venugopalan V; Klinker K; Peloquin C
    J Antimicrob Chemother; 2020 Dec; 75(12):3644-3651. PubMed ID: 32910809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
    Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.
    Udy AA; Varghese JM; Altukroni M; Briscoe S; McWhinney BC; Ungerer JP; Lipman J; Roberts JA
    Chest; 2012 Jul; 142(1):30-39. PubMed ID: 22194591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
    Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
    Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study.
    Carrié C; Petit L; d'Houdain N; Sauvage N; Cottenceau V; Lafitte M; Foumenteze C; Hisz Q; Menu D; Legeron R; Breilh D; Sztark F
    Int J Antimicrob Agents; 2018 Mar; 51(3):443-449. PubMed ID: 29180280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia.
    Maranchick NF; Trillo-Alvarez C; Kariyawasam V; Venugopalan V; Kwara A; Rand K; Peloquin CA; Alshaer MH
    Ther Drug Monit; 2024 Feb; 46(1):95-101. PubMed ID: 38018847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-lactam target attainment and associated outcomes in patients with bloodstream infections.
    Alshaer MH; Maranchick N; Alexander KM; Manigaba K; Shoulders BR; Felton TW; Mathew SK; Peloquin CA
    Int J Antimicrob Agents; 2023 Mar; 61(3):106727. PubMed ID: 36646230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia.
    Alshaer MH; Maranchick N; Bai C; Maguigan KL; Shoulders B; Felton TW; Mathew SK; Mardini MT; Peloquin CA
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0056322. PubMed ID: 35699444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
    Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.
    Lee YR; Miller PD; Alzghari SK; Blanco DD; Hager JD; Kuntz KS
    Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):155-170. PubMed ID: 29027128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic modifications and pharmacokinetic/pharmacodynamic optimization of beta-lactams in ICU].
    Matusik E; Lambiotte F; Tone A; Lemtir J
    Ann Pharm Fr; 2021 Jul; 79(4):346-360. PubMed ID: 33309603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients.
    Beumier M; Casu GS; Hites M; Wolff F; Cotton F; Vincent JL; Jacobs F; Taccone FS
    Minerva Anestesiol; 2015 May; 81(5):497-506. PubMed ID: 25220556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill.
    Wong G; Taccone F; Villois P; Scheetz MH; Rhodes NJ; Briscoe S; McWhinney B; Nunez-Nunez M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2020 Feb; 75(2):429-433. PubMed ID: 31665353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
    Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
    Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy.
    Imani S; Buscher H; Day R; Gentili S; Jones GRD; Marriott D; Norris R; Sandaradura I
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2171-2175. PubMed ID: 30120647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study.
    Patel BM; Paratz J; See NC; Muller MJ; Rudd M; Paterson D; Briscoe SE; Ungerer J; McWhinney BC; Lipman J; Roberts JA
    Ther Drug Monit; 2012 Apr; 34(2):160-4. PubMed ID: 22406650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological burden and outcomes of excessive β-lactam serum concentrations of critically ill septic patients: a prospective cohort study.
    Zerbib Y; Gaulin C; Bodeau S; Batteux B; Lemaire-Hurtel AS; Maizel J; Kontar L; Bennis Y
    J Antimicrob Chemother; 2023 Nov; 78(11):2691-2695. PubMed ID: 37694500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.
    Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.